| Literature DB >> 21170131 |
Alaaldin M Alkilany1, Catherine J Murphy.
Abstract
Gold nanoparticles have attracted enormous scientific and technological interest due to their ease of synthesis, chemical stability, and unique optical properties. Proof-of-concept studies demonstrate their biomedical applications in chemical sensing, biological imaging, drug delivery, and cancer treatment. Knowledge about their potential toxicity and health impact is essential before these nanomaterials can be used in real clinical settings. Furthermore, the underlying interactions of these nanomaterials with physiological fluids is a key feature of understanding their biological impact, and these interactions can perhaps be exploited to mitigate unwanted toxic effects. In this Perspective we discuss recent results that address the toxicity of gold nanoparticles both in vitro and in vivo, and we provide some experimental recommendations for future research at the interface of nanotechnology and biological systems.Entities:
Year: 2010 PMID: 21170131 PMCID: PMC2988217 DOI: 10.1007/s11051-010-9911-8
Source DB: PubMed Journal: J Nanopart Res ISSN: 1388-0764 Impact factor: 2.253
Fig. 1Gold nanorods of different aspect ratios have different colors and tunable ultraviolet–visible–near-infrared spectra. Scale bars in the transmission electron micrographs at the top are 100 nm
Fig. 2Schematic showing the physical events that occur as a result of satisfying the localized surface plasmon resonance condition, with the corresponding applications. See text for details
Fig. 3(Upper panel): Cartoon demonstrating the formation of protein corona on a gold nanoparticle surface. Adsorption of serum proteins onto the surface of gold nanoparticles flips their effective surface charge. (Lower panel): Effective surface charge (zeta potential) of gold nanorods capped with cetyltrimethylammonium bromide, CTAB (white bars) and poly(acrylic acid), PAA (black bars). In aqueous solution, CTAB-capped gold nanorods have a positive effective surface charge and PAA-coated nanorods are negative. However, both have the same negative effective surface charge after they mixed with serum proteins and subsequently purified
Fig. 4“The supernatant control”. A gold nanorod solution is exposed to cells, and in this cartoon kills 70% of the cells at a certain dose. An identical gold nanorod solution is centrifuged, and the colorless supernatant exposed to cells. The similar toxicity of both solutions indicates that the nanoparticles are not toxic by themselves, but small molecules (leftover reagents, or desorbed capping agents) are
Summary of in vitro gold nanoparticle toxicity results
| Cell line | Nanoparticle dimensions (nm) | Nanoparticle shape | Nanoparticle surface group | Dosea; incubation time | Conclusions | Ref. |
|---|---|---|---|---|---|---|
| COS-1 mammalian cells, red blood cells, | 2 | Spheres | Quaternary ammonium, carboxylic acid | 0.38–3 μM; 1–24 h | Cationic nanoparticles found to be toxic where anionic not | Goodman et al. |
| RAW 264.7 mouse macrophage | 3.5 ± 0.7 | Spheres | Lysine, poly(lysine) | 10–100 μM; 24–72 h | Nanoparticles are not toxic and not immunogenic | Shukla et al. ( |
| K562 human leukemia | 4, 12, 18 | Spheres | CTAB, citrate, cysteine, glucose, biotin | 0.001–0.25 μM; 72 h | All nanoparticles were not toxic | Connor et al. ( |
| MV3 and BLM (Metastatic melanoma) | 1.4 | Spherical cluster | Triphenylphosphine monosulfonate | Up to 0.4 μM; 72 h | 100% cell death at 0.4 μM compared to 10% cell death for cisplatin at same concentration | Tsoli et al. ( |
| HeLa | 65 × 11 | Rods | CTAB, PEG | 0.09–1.45 μM; 24 h | Replacing CTAB with PEG on the surface of nanorods reduced the toxicity | Takahashi et al. ( |
| Human dermal fibroblast | 13.1 | Spheres | Citrate | 0–4 mM; 24–144 h | Nanoparticles decreased cell proliferation rate, adhesion, and motility | Pernodet et al. ( |
| (1) baby hamster kidney cells BHK21 | 33 | Spheres | CTAB and citrate | 0–120 nM; 36 h for A549 and 72 h for both Hep2G and BHK21 | Nanoparticles are not toxic to Hep2G and BHK21 but to A549 cell line | Patra et al. ( |
| (2) Human liver carcinoma Hep2G | ||||||
| (3) Human lung carcinoma cells A549 | ||||||
| HeLa | 18 | Spheres | Citrate | 0.2–2 nM; 3–6 h | Nanoparticles are not toxic and did not change gene-expression patterns | Khan et al. ( |
| (1) Epithelial: HeLa | 0.8, 1.2, 1.4, 1.8, 15 | Spheres | Triphenylphosphine mono and tri-sulfonate | Up to 5.6 μM; 72 h | (a) 1.4 nm: Most toxic size; (b) 0.8, 1.2, 1.8:4–6 fold toxicity compared to 1.4 nm; (c) 15 nm: completely non toxic; (d) toxicity is not cell line dependent | Pan et al. ( |
| (2) Endothelial: SK-Mel-28 | ||||||
| (3) Fibroblasts: L929 | ||||||
| (4) Phagocytes: j774A1 | ||||||
| HeLa | 40 × 18 | Rods | CTAB, PSS, PDADMAC | 10–150 μM; 6 h | Polyelectrolyte coating of nanorods are not toxic compared to the CTAB-capped nanorods and no gene expression abnormalities were observed | Hauck et al. ( |
| Dendritic cells from C57BL/6 mice | 10 | Spheres | Citrate | 0.5 mM; 4–48 h | Nanoparticles were not toxic and did not induce dendritic cell activation | Villiers et al. ( |
| HeLa | 1.4 and 1.5 | Spheres | Triphenylphosphine monosulfonate, GSH | 5.6 mM; 48 h | (a) The 1.4 nanoparticles induced necrosis by oxidative stresses where the 15 nm particles were found to be not toxic; (b) GSH-capped nanoparticles were less toxic than TPMS-capped nanoparticles | Pan et al. ( |
| HeLa | 3.7 | Spheres | PEG | 0.08–100 μM; 6–72 h | Nanoparticles entered nucleus and did not induce toxicity | Gu et al. ( |
| HT-29 (Human colon carcinoma cells) | 65 × 15 nm | Rods | CTAB, PAA, PAH | 0.6 nM; 96 h | Nanorods are not toxic, excess CTAB is. Overcoating the CTAB-capped rods with either negatively or positively charged polymers reduces toxicity and affects their uptake | Alkilany et al. ( |
CTAB cetyl trimethylammonium bromide, cationic surfactant; PEG poly(ethylene glycol); PSS poly(sodium 4-styrenesulfonate), anionic polyelectrolyte; PDADMAC poly(diallyldimethylammonium chloride), cationic polyelectrolyte; PAA poly(acrylic acid, sodium salt), anionic polyelectrolyte; PAH poly(allylamine hydrochloride), cationic polyelectrolyte; GSH glutathione
aDoses are calculated from original papers in gold atom concentrations
Summary of in vitro gold nanoparticle uptake results
| Cell line | Nanoparticle dimensions (nm) | Nanoparticle shape | Nanoparticle surface group | Dosea; incubation time | Cellular uptake (gold nanoparticles/cell) | Analytical method | Ref. |
|---|---|---|---|---|---|---|---|
| HeLa | 40 × 18 (length × width) | Rods | CTAB, PAH, PSS, PDADMAC | 1.0 nM; 6 h | 150,000 for PDAMAC; 12,000 for PAH; 12,000 for CTAB; 1,000 for PSS | ICP-AES | Hauck et al. ( |
| HT-29 | 65 × 15 (length × width) | Rods | CTAB, PAA, PAH | 0.2 nM; 96H | 45 ± 6 for CTAB; 270 ± 20 for PAA; 2,320 ± 140 for PAH | ICP-MS | Alkilany et al. ( |
| SK-BR-3 | 17.7 | Spheres | Citrate, PAH, PVA | 0.027 nM; 24 h | 1,800 for citrate; 5,200 for PAH; 900 for PVA | ICP-MS | Cho et al. ( |
| SK-BR-3 | 50 × 20 (length × width) | Rods | CTAB, PEG, anti-HER2 | 0.06 nM; 24 h | 8,000 for CTAB; 3,000 for PEG; 4,400 for anti-HER2 | ICP-MS | Cho et al. ( |
| U87MG | 50 × 5 nm (edge length × wall thickness) | Cages | Anti-EGFR, PEG | 0.02 nM; 24 h | 826 ± 50 for anti-EGFR and 190 ± 31 for PEG | ICP-MS | Au et al. ( |
CTAB Cetyl trimethylammonium bromide, cationic surfactant; PDADMAC poly(diallyldimethylammonium chloride), cationic polyelectrolyte; PAH poly(allylamine hydrochloride), cationic polyelectrolyte; PAA poly(acrylic acid, sodium salt), anionic polyelectrolyte; PSS poly(sodium 4-styrenesulfonate), anionic polyelectrolyte; PVA poly(vinyl alcohol) slightly anionic polymer; PEG poly(ethylene glycol), neutral polymer; Anti-HER monoclonal antibodies that recognize human epidermal growth factor 2 (HER2) receptors, anti-EGFR monoclonal antibodies that recognize epidermal growth factor (EGER) receptors, ICP-AES inductively-coupled plasma atomic emission spectroscopy, ICP-MS inductively-coupled plasma mass spectrometry
aDoses and cellular uptake values are calculated from the original papers in gold nanoparticle (not atoms) concentration
Summary of in vivo gold nanoparticle toxicity/pharmacokinetic results
| Animal | Nanoparticle dimensions (nm); shape | Nanoparticle surface group | Administration route; Dosea | Time of exposure (h) | Number of studied animals ( | Conclusions | Ref |
|---|---|---|---|---|---|---|---|
| Mice (ddy) | 65 × 11; rods | Polyethylene glycol, CTAB | Intravenous: 0.03–0.054 mg gold/mouse | 0.5–72 | 3 | PEG modification of gold nanorods increase the blood circulation time: after 0.5 min of injection, most of the CTAB-capped nanorods accumulated in the liver where 54% of PEG-capped nanorods found in the blood | Niidome et al. ( |
| Pigs | 15–20, spheres | Arabic gum | Intravenous: 0.8–1.88 mg gold/kg | 0.5–24 | 3 | Nanoparticles accumulated in lung and liver; no hematological or renal side effects were observed | Kattumuri et al. ( |
| Mice (ddy) | 15, 50, 100, 200; spheres | Citrate | Intravenous: 1000 mg gold/kg | 24 | 3 | All sizes were found in liver, spleen, lung. 15 and 50 nm nanoparticles were found also in heart, stomach, kidney, and the brain | Sonavane et al. ( |
| Rats | 10, 50, 100, 250; spheres | Not reported | Intravenous: 77–108 µg/rat | 24 | 4 | No side effect was observed. Most nanoparticles were found in spleen and liver; the 10 nm particles were found also in brain, heart, kidney, testis, and thymus | De Jong et al. ( |
| Mice (BALB/c) | 4, 10, 28, 58; spheres | Citrate | Oral: Mixed with drinking water (200 mg gold/kg water) | 168 | Not reported | Gastrointestinal uptake by persorption, more readily for smaller particles | Hillyer and Albrecht ( |
| Mice (BALB/c) | 3, 5, 8, 12, 1737, 50, 100; spheres | Citrate | Intraperitonical: 8 mg gold/kg | >1200 | 6 | 3, 5, 50, 100 nm particles did not induce any lethality were particles with diameter on the range of 8.37 nm did | Chen et al. ( |
| Mice (BALB/c) | 13; spheres | Polyethyene glycol | Intravenous up to 4.26 mg gold/kg | up to 168 | 9 | Nanoparticles induced inflammation and apoptosis in the liver tissue | Cho et al. ( |
| Zebrafish | 3, 10, 50, 100; spheres | Citrate | Exposure in water of concent rations of: 250, 25, 2.5, 0.25 µM | 120 | 12 | Nanoparticles were taken up by zebrafish and did not induce any toxicity | Bar-Ilan et al. ( |
| Mice (BALB/c) | 20, 40, 80; spheres | Polyethylene glycol | Intravenous: 34–2210 mg gold/kg(same number of nanoparticles per mouse) | 48 | 8 | Biodistribution and cancer accumulation of nanoparticles is size dependent; smaller nanoparticles have longer blood circulation time and more tumor accumulation | Zhang et al. ( |
| Entire estuarine mesocosms containng: Fish, shrimp, snail, clams, and microbial biofilm | 65 × 15; rods | CTAB | Exposure in the estuarine mesocosms; initial concentration of 116 µM | 288 | 15 fish, 100 shrimps, 50 snails, and 100 clams | Gold nanorods partition efficiently into the food web and did not induce any mortality; clams and microbial biofilms accumulate the most gold | Ferry et al. ( |
CTAB cetyl trimethylammonium bromide, cationic surfactant
aDoses are calculated from the original papers in gold atom concentrations
Fig. 5Left: average lifespan of mice receiving gold nanoparticles, 8–37 nm in diameter, was shortened compared to smaller and larger nanoparticle sizes. The break marks on the top of bars indicate that no death was observed during the experimental period. Right: MTT assay for the same gold nanoparticles using the HeLa cell line. Images reproduced with permission from (Chen et al. 2009). Copyright: Springer Science
Fig. 6Cartoon demonstrates the concept of the biodegradable plasmon-resonant liposomes. The whole composite absorbs in the near-infrared region and thus serve as “nanoheaters” to destroy cancer cells. Upon disruption of the carrier (liposomes), the nanoparticles could be released and have a higher chance to be bio-eliminated